Skip to main content
Premium Trial:

Request an Annual Quote

Response Biomedical CEO Resigns

NEW YORK (GenomeWeb News) – Response Biomedical late Friday announced the resignation of its CEO Wayne Kay, effective immediately. Kay also resigned as a director of the Vancouver, British Columbia-based diagnostics company.

Peter Thompson will serve as executive chairman and interim CEO, and Reponse Bio has retained an executive search firm to seek a permanent CEO.

Kay's resignation came two days after the firm announced a 17 percent increase in its second-quarter revenues. During the quarter, though, its submission to the US Food and Drug Administration for 510(k) clearance of its NTproBNP assay for the diagnosis of heart failure on its Ramp 200 platform had been turned down.

Kay had previously served as CEO of venture capital firm Kleiner Perkins Caufield & Byers, and was president and CEO of Quidel.

The Scan

Science Confidence Boost

The New York Times reports that a new poll finds trust in science and scientists has increased with the COVID-19 pandemic.

Appeal and Funds

Some grant applications denied funding due to an Australian Research Council rule change have now been funded following an appeal, the Guardian reports.

Surveillance for Variants

Vox writes that the detection of the Omicron SARS-CoV-2 variant highlights the need for improved viral genomic surveillance.

Nature Papers Examine Taxonomic Gaps in Plant Sequencing, SARS-CoV-2-Human Interactome

In Nature this week: plant genome sequencing dominated by affluent countries, and more.